JSKN016 clinical trials
Also written JSKN016.
How each study uses JSKN016 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the JSKN016 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Jiangsu Alphamab Biopharmaceuticals Co., Ltd (5) · Shanghai Pulmonary Hospital, Shanghai, China (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test JSKN016.
- Jan 2027Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer PatientsPhase 2 · Shanghai Pulmonary Hospital, Shanghai, China
- Jun 2027Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance: a Phase II Clinical StudyPhase 2 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Jun 2027Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast CancerPhase 1/2 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Studies
Open first, then newest update. How each study uses JSKN016 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of CareRecruitingPhase 3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT07533123Written as JSKN016 Injection
- Evaluation of JSKN016 Combination Therapy in Subjects With NSCLCRecruitingPhase 1Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06868732Written as JSKN016
- Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer PatientsNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT07493980Written as JSKN016 + Toripalimab + Carboplatin
- Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast CancerRecruitingPhase 1/2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06942234Written as JSKN016
- Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance: a Phase II Clinical StudyNot yet recruitingPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06775483Written as JSKN016
- To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid TumorsRecruitingPhase 1Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06592417Written as JSKN016 injection